connect with us
For further information please fill the details below:
Skip to main content

Biomedical Research Journal


Volume 2, Issue 1, April 2015, Pages 06-20


Advances in omics technologies in GBM

Uday B. Maachani, Uma Shankavaram, Kevin Camphausen and Anita Tandle*

Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD, USA

Abstract : 

Glioblastoma multiforme (GBM) is one of the most lethal human cancers and poses a great challenge in the therapeutic interventions of GBM patients worldwide. Despite prominent recent advances in oncology, on an average GBM patients survive 12–15 months with conventional standard of care treatment. To understand the pathophysiology of this disease, recently the research focus has been on omics-based approaches. Advances in high-throughput assay development and bioinformatic techniques have provided new opportunities in the molecular analysis of cancer omics technologies including genomics, transcriptomics, epigenomics, proteomics, and metabolomics. Further, the enormous addition and accessibility of public databases with associated clinical demographic information including tumor histology, patient response and outcome, have profoundly improved our knowledge of the molecular mechanisms driving cancer. In GBM, omics have significantly aided in defining the molecular architecture of tumorigenesis, uncovering relevant subsets of patients whose disease may require different treatments. In this review, we focus on the unique advantages of multifaceted omics technologies and discuss the implications on translational GBM research.

Key words:

Glioblastoma, Omics, Genomics, Transcriptomics, Epigenomics, Proteomics, Metabolomics

*Corresponding Author:

Anita Tandle, Radiation Oncology Branch, National Cancer Institute, 10 Center Drive Magnuson Clinical Center Room B3-B100, Bethesda MD 20892, USA. Email:

Cite this article as:

Maachani UB, Shankavaram U, Camphausen K, Tandle A. Advances in omics technologies in GBM. Biomed Res J. 2015;2(1):6–20.

Connect With Us x